Cytokines, reverse genetics and anti-cytokine therapy

Cytokines comprise the molecular language of communication between the cells, which is needed to maintain the homeostatic functions of the body (including the immune system) and mediate various diseases. Many aspects of inflammation, autoimmune diseases and neoplasia are associated with cytokine signaling through specific receptors. The establishment of new physiological functions of “old” cytokines and understanding the molecular and cellular mechanisms of their involvement in disease pathogenesis, as well as the search for new therapeutic targets and development of innovative approaches to anti-cytokine therapy, present a fundamental problem. When assessing the tremendous success of anti-cytokine therapy in treatment of certain autoimmune diseases, we should not forget that (a) this treatment does not eliminate the causes of the disease:autoreactive T-cell clones; and that (b) less than half of the patients respond to this therapy; and that (c) anti-cytokine therapy has serious side effects.

1. Maini R.N., Elliott M., Brennan F.M., Williams R.O., Feldmann M. Targeting TNF alpha for the therapy of rheumatoid arthritis. Clin. Exp. Rheumatol. 1994; 12 (Suppl. 11): 63–66.

2. Tumanov A., Kuprash D., Lagarkova M., Grivennikov S., Abe K., Shakhov A., Drutskaya L., Stewart C., Chervonsky A., Nedospasov S. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity. 2002; 17 (3): 239–250. DOI: 10.1016/S1074-7613(02)00397-7.

3. Grivennikov S.I., Tumanov A.V., Liepinsh D.J., Kruglov A.A., Marakusha B.I., Shakhov A.N., Murakami T., Drutskaya L.N., Forster I., Clausen B.E. et al. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity. 2005; 22 (1): 93–104. DOI: 10.1016/j.immuni.2004.11.016.

4. Kruglov A.A., Grivennikov S.I., Kuprash D.V., Winsauer C., Prepens S., Seleznik G.M., Eberl G., Littman D.R., Heikenwalder M., Tumanov A.V. et al. Nonredundant function of soluble LTalpha3 produced by innate lymphoid cells in intestinal homeostasis. Science. 2013; 342 (6163): 1243–1246. DOI: 10.1126/science.1243364.

5. Alimzhanov M.B., Kuprash D.V., Kosco-Vilbois M.H., Luz A., Turetskaya R.L., Tarakhovsky A., Rajewsky K., Nedospasov S.A., Pfeffer K. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94 (17): 9302–9307.

6. Kruglov A.A., Lampropoulou V., Fillatreau S., Nedospasov S.A. Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. Journal of Immunology. 2011; 187 (11): 5660–5670. DOI: 10.4049/jimmunol.1100663.

7. Drutskaya M.S., Efimov G.A., Astrakhantseva I.V., Kruglov A.A., Nedospasov S.A. Making anti-cytokine therapy more selective: Studies in mice. Cytokine. 2018; 101: 33–38. DOI: 10.1016/j.cyto.2016.08.022.

8. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995; 83 (5): 793–802.

9. Chen X., Wu X., Zhou Q., Howard O.M., Netea M.G., Oppenheim J.J. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T cell phenotype in the inflammatory environment. Journal of Immunology. 2013; 190 (3): 1076–1084. DOI: 10.4049/jimmunol.1202659.

10. Atretkhany K.-S.N., Mufazalov I.A., Dunst J., Kuchmiy A., Gogoleva V.S., Andruszewski D., Drutskaya M.S., Faustman D.L., Schwabenland M., Prinz M. et al. Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115 (51): 13051–13056. DOI: 10.1073/pnas.1807499115.

11. Efimov G.A., Kruglov A.A., Khlopchatnikova Z.V., Rozov F.N., Mokhonov V.V., Rose-John S., Scheller J., Gordon S., Stacey M., Drutskaya M.S. et al. Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source. Proceedings of the National Academy of Sciences of the United States of America. 2016; 113 (11): 3006–3011. DOI: 10.1073/pnas.1520175113.

12. Nosenko M.A., Atretkhany K.N., Mokhonov V.V., Efimov G.A., Kruglov A.A., Tillib S.V., Drutskaya M.S., Nedospasov S.A. VHH-Based Bispecific Antibodies Targeting Cytokine Production. Frontiers in Immunology. 2017; 8: 1073. DOI: 10.3389/fimmu.2017.01073.

13. Allie N., Grivennikov S.I., Keeton R., Hsu N.J., Bourigault M.L., Court N., Fremond C., Yeremeev V., Shebzukhov Y., Ryffel B. et al. Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. Sci. Rep. 2013; 3: 1809. DOI: 10.1038/srep01809.

14. Kroetsch J.T., Levy A.S., Zhang H., Aschar-Sobbi R., Lidington D., Offermanns S., Nedospasov S.A., Backx P.H., Heximer S.P., Bolz S.S. Constitutive smooth muscle tumour necrosis factor regulates microvascular myogenic responsiveness and systemic blood pressure. Nat. Commun. 2017; 8: 14805. DOI: 10.1038/ncomms14805.

15. Drutskaya M.S., Efimov G.A., Kruglov A.A., Nedospasov S.A. Can we design a better anti-cytokine therapy? J. Leukoc. Biol. 2017; 102 (3): 783–790. DOI: 10.1189/jlb.3MA0117-025R.

16. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014; 6 (10): a016295. DOI: 10.1101/cshperspect.a016295.

17. Gubernatorova G.O., Gorshkova E.A., Namakanova O.A., Zvartsev R.V., Hidalgo J., Drutskaya M.S., Tumanov A.V., Nedospasov S.A. Non-redundant functions of IL-6 produced by macrophages and dendritic cells in allergic airway inflammation. Frontiers in Immunology. 2018; 9: 2718. DOI: 10.3389/fimmu.2018.02718.

18. Zvartsev R.V., Korshunova D.S., Gorshkova E.A., Nosenko M.A., Korneev K.V., Maximenko O.G., Korobko I.V., Kuprash D.V., Drutskaya M.S., Nedospasov S.A., Deikin A.V. Neonatal lethality and inflammatory phenotype of new transgenic mice with overexpression of human interleukin-6 in myeloid cells. Dokl. Biochem. Biophys. 2018; 483 (1): 344–347 (in Russ.). DOI: 10.1134/S1607672918060157.

19. Heink S., Yogev N., Garbers C., Herwerth M., Aly L., Gasperi C., Husterer V., Croxford A.L., Moller-Hackbarth K., Bartsch H.S. et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat. Immunology. 2017; 18 (1): 74–85. DOI: 10.1038/ni.3632.

20. Rose-John S., Winthrop K., Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nature Reviews. Rheumatology. 2017; 13 (7): 399–409. DOI: 10.1038/nrrheum.2017.83.